ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Causal Risk Factors for Type 1 Diabetes in Mendelian Randomization Studies: A Systematic Review and Meta-Analysis.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 1 diabetes mellitus (T1DM) is a chronic disease mediated by autoimmunity, with complex and not fully elucidated pathogenesis. Mendelian randomization (MR) utilizes genetic instrumental variables to minimize confounding and reverse causation; however, individual MR studies are often limited by sample size and result heterogeneity. Methods: Following PRISMA 2020 guidelines, we systematically searched PubMed, Web of Science, and other databases from 2014 to 2025, ultimately including 53 MR studies (covering 243 exposures). Random-effects models were used to pool effect sizes. Heterogeneity was quantified by Cochran's Q test and I Results: This study integrated 53 MR studies (243 exposures) and identified key causal factors for T1DM.IL2RA (OR = 0.22, 95% CI: 0.17-0.27) and TYK2 (OR = 0.61, 95% CI: 0.54-0.69) showed significant protective effects, while IL6R (OR = 1.98, 95% CI: 1.48-2.65) was associated with increased risk. For metabolites, 3-phenylpropionic acid (OR = 0.90, 95% CI: 0.85-0.96) and cinnamoylglycine (OR = 0.89, 95% CI: 0.84-0.96) were protective, while trimethylamine N-oxide (TMAO; OR = 1.11, 95% CI: 1.02-1.20) increased risk. Among gut microbiota, Prevotella 9 (OR = 1.18, 95% CI: 1.08-1.30) was positively associated with risk, whereas Bifidobacterium (OR = 0.82, 95% CI: 0.71-0.95) showed a protective effect. Childhood obesity (OR = 1.32, 95% CI: 1.06-1.64) was also associated with increased T1DM risk. Overall heterogeneity was high (I Conclusion: This study systematically mapped the multi-omics causal risk landscape of T1DM, providing important evidence for precision prevention and targeted intervention. These findings suggest that targeting immune pathways (particularly IL2RA and TYK2) and modulating gut microbiota composition may represent promising strategies for T1DM prevention. Future research should emphasize cross-ethnic validation and life-stage-specific intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.